
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc has demonstrated significant growth, particularly in its point-of-care (POC) and formulary offerings, which experienced over 100% growth during the most recent buying season, indicating strong demand among medical professionals. Following recent positive developments, the company’s shares have seen a modest increase of 3.2% since early September, reflecting growing investor confidence. Additionally, Doximity's second-quarter guidance appears attainable, with the potential for upside, bolstered by increased visibility from expanded offerings and heightened upfront buying activity.
Bears say
Doximity Inc is experiencing negative financial pressures due to uncertainty in the economic environment, which has resulted in downward guidance revisions from its pharmaceutical clients for fiscal years 2023 and 2024. The company's stock is perceived as expensive relative to its software peers, leading to potential volatility should the firm fail to meet high investor expectations. Additionally, there is significant scrutiny on Doximity's financial performance, and any failure to deliver positive results or raise guidance may be regarded as a disappointment in the market.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares